Jason Gerberry
Stock Analyst at B of A Securities
(4.24)
# 419
Out of 5,149 analysts
166
Total ratings
61.98%
Success rate
11.1%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $263 → $275 | $186.67 | +47.32% | 7 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Underperform | $32 → $28 | $28.27 | -0.96% | 3 | Feb 25, 2026 | |
| ALKS Alkermes | Maintains: Neutral | $33 → $34 | $29.20 | +16.44% | 10 | Feb 20, 2026 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.58 | +5.34% | 5 | Dec 15, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $64.10 | +26.37% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $78.66 | +23.32% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $32.28 | -0.87% | 15 | Dec 9, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $27.57 | +5.19% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $19.83 | +61.37% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $26.71 | +12.32% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $49 | $10.67 | +359.23% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $173 → $176 | $164.05 | +7.28% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $2.21 | -54.75% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $31.78 | -27.63% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $40.74 | +12.91% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $59.82 | +129.02% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $14.89 | -32.84% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $23.92 | +25.42% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $114.05 | -12.32% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $9.85 | +143.65% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $33.05 | -6.20% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $1.24 | +44,254.84% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $43.79 | +27.88% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $1,007.73 | -50.38% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.53 | +255.73% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $6.90 | +262.32% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.55 | +222.58% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.73 | +371.20% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.65 | +1,112.12% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $5.12 | +1,853.13% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $233.86 | -59.38% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $61.22 | -1.99% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $119.83 | -24.89% | 11 | Oct 17, 2019 |
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $263 → $275
Current: $186.67
Upside: +47.32%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Underperform
Price Target: $32 → $28
Current: $28.27
Upside: -0.96%
Alkermes
Feb 20, 2026
Maintains: Neutral
Price Target: $33 → $34
Current: $29.20
Upside: +16.44%
Pfizer
Dec 15, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.58
Upside: +5.34%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $64.10
Upside: +26.37%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $78.66
Upside: +23.32%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $32.28
Upside: -0.87%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $27.57
Upside: +5.19%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $19.83
Upside: +61.37%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $26.71
Upside: +12.32%
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $10.67
Upside: +359.23%
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $164.05
Upside: +7.28%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.21
Upside: -54.75%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $31.78
Upside: -27.63%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $40.74
Upside: +12.91%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $59.82
Upside: +129.02%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $14.89
Upside: -32.84%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.92
Upside: +25.42%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $114.05
Upside: -12.32%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $9.85
Upside: +143.65%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $33.05
Upside: -6.20%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $1.24
Upside: +44,254.84%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $43.79
Upside: +27.88%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $1,007.73
Upside: -50.38%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.53
Upside: +255.73%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $6.90
Upside: +262.32%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.55
Upside: +222.58%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.73
Upside: +371.20%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.65
Upside: +1,112.12%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $5.12
Upside: +1,853.13%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $233.86
Upside: -59.38%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $61.22
Upside: -1.99%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $119.83
Upside: -24.89%